[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622695":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":33,"locations":42,"responsibleParty":60,"collaborators":25,"id":62,"slug":25,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":25,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":25,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":25,"overallStatus":81,"whyStopped":25,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Radicle Science","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo Clarity Control","PLACEBO_COMPARATOR","Clarity Product Placebo Control",[13],"Dietary Supplement: Clarity Product Placebo Control",{"label":15,"type":16,"description":17,"interventionNames":18},"Active Clarity Product","EXPERIMENTAL","Clarity Active Product",[19],"Dietary Supplement: Clarity Active Product",[21,26],{"type":22,"name":11,"description":23,"armGroupLabels":24,"otherNames":25},"DIETARY_SUPPLEMENT","Participants will use their Clarity Product Placebo Control as directed for a period of 8 weeks",[9],null,{"type":22,"name":17,"description":27,"armGroupLabels":28,"otherNames":25},"Participants will use their Clarity Active Product as directed for a period of 8 weeks",[15],[30],{"name":31,"affiliation":5,"role":32},"Susan Hewlings","PRINCIPAL_INVESTIGATOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":25,"email":38},"Study Manager","CONTACT","858-779-0086","studymgmt@radiclescience.com",{"name":31,"role":36,"phone":40,"phoneExt":25,"email":41},"760-281-3898","susan.hewlings@radiclescience.com",[43],{"facility":44,"status":25,"city":45,"state":46,"zip":47,"country":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Radicle Science Inc.","Del Mar","California","92014","United States",{"type":50,"coordinates":51},"Point",[52,53],-117.26531,32.95949,{"lat":53,"lon":52},[56,57],{"name":35,"role":36,"phone":40,"phoneExt":25,"email":38},{"name":58,"role":36,"phone":25,"phoneExt":25,"email":59},"Megan Moseley","megan@radiclescience.com",{"type":61,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100622695",false,"NCT07386964","Radicle Clarity CNM™: A Study Assessing the Impact of Health and Wellness Products on Cognitive Function and Related Health Outcomes Among E-Gamers","Radicle Clarity CNM™: A Randomized, Double-Blind, Placebo-Controlled Direct-to-Consumer Study Assessing the Impact of Health and Wellness Products on Cognitive Function and Related Health Outcomes Among E-Gamers","Inclusion\n\nParticipants must meet all the following criteria:\n\n* Adults, aged 21 - 45 years at the time of electronic consent, inclusive of all ethnicities, races, and gender identities\n\n  * Assigned sex at birth will determine sex-specific recruitment and surveys (male vs female) employed, when needed\n* Identifies as a young professional (working 30+ hrs\u002Fweek)\n* May identify as an E-gamer (playing video games 5+hrs\u002Fweek for the past year)\n* Resides in the United States\n* Has the opportunity for at least 30% improvement in their primary health outcome\n* Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study\n\nExclusion\n\nIndividuals who report any of the following during screening may be excluded from participation:\n\n* Report being pregnant, trying to become pregnant, or breastfeeding\n* Unable to provide a valid US shipping address and mobile phone number\n* Reports current enrollment in another clinical trial\n* Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)\n* Unable to read and understand English at a 7th grade level\n* Reports a current and\u002For recent (up to 3 months ago) major illness and\u002For surgery that poses a known, significant safety risk.\n* Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and\u002For a significant safety risk with any of the study product ingredients.\n\n  * NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure\n* Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients.",true,"ALL","21 Years","45 Years",{"count":73,"type":74},600,"ESTIMATED","INTERVENTIONAL",[77],"NA","Radicle Clarity CNM™: A randomized, double-blind, placebo-controlled direct-to-consumer study assessing the impact of health and wellness products on cognitive function and related health outcomes among E-Gamers.",[80],"Cognitive Function","NOT_YET_RECRUITING","2026-01-28",{"date":84,"type":85},"2026-02-04","ACTUAL",{"date":87,"type":74},"2026-02-26",{"date":89,"type":74},"2027-02-26",{"name":5,"class":6},1]